The early-life gut microbiome and vaccine efficacy

Anne Jordan; Simon R. Carding; Lindsay J. Hall

doi:10.1016/S2666-5247(22)00185-9

The early-life gut microbiome and vaccine efficacy

Anne Jordan, Simon R. Carding, Lindsay J. Hall^*

^*Corresponding author for this work

Microbiology and Infection

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

18 Downloads (Pure)

Abstract

Vaccines are one of the greatest successes of public health, preventing millions of cases of disease and death in children each year. However, the efficacy of many vaccines can vary greatly between infants from geographically and socioeconomically distinct locations. Differences in the composition of the intestinal microbiome have emerged as one of the main factors that can account for variations in immunisation outcomes. In this Review, we assess the influence of the gut microbiota upon early life immunity, focusing on two important members of the microbiota with health-promoting and immunomodulatory properties: Bifidobacterium and Bacteroides. Additionally, we discuss their immune stimulatory microbial properties, interactions with the host, and their effect on vaccine responses and efficacy in infants. We also provide an overview of current microbiota-based approaches to enhance vaccine outcomes, and describe novel microbe-derived components that could lead to safer, more effective vaccines and vaccine adjuvants.

Original language	English
Pages (from-to)	e787-e794
Number of pages	8
Journal	The Lancet Microbe
Volume	3
Issue number	10
Early online date	8 Sept 2022
DOIs	https://doi.org/10.1016/S2666-5247(22)00185-9
Publication status	Published - Oct 2022

Bibliographical note

Funding Information:
LJH is supported by Wellcome Trust Investigator Awards (100974/C/13/Z and 220876/Z/20/Z). LJH and SRC are also supported by Biotechnology and Biological Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1) and its constituent projects (BBS/E/F/000PR10353, BBS/E/F/000PR10355, and BBS/E/F/000PR10356), and a BBSRC Norwich Research Park Bioscience Doctoral Training grant (BB/M011216/1; supervisors LJH and SRC, student AJ).

Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

ASJC Scopus subject areas

Microbiology
Microbiology (medical)
Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2666-5247(22)00185-9Licence: Creative Commons: Attribution (CC BY)

JordanA2022earlyFinal published version, 1.2 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{dbbd3ab5edc64a3283e47dc7a4c6215c,

title = "The early-life gut microbiome and vaccine efficacy",

abstract = "Vaccines are one of the greatest successes of public health, preventing millions of cases of disease and death in children each year. However, the efficacy of many vaccines can vary greatly between infants from geographically and socioeconomically distinct locations. Differences in the composition of the intestinal microbiome have emerged as one of the main factors that can account for variations in immunisation outcomes. In this Review, we assess the influence of the gut microbiota upon early life immunity, focusing on two important members of the microbiota with health-promoting and immunomodulatory properties: Bifidobacterium and Bacteroides. Additionally, we discuss their immune stimulatory microbial properties, interactions with the host, and their effect on vaccine responses and efficacy in infants. We also provide an overview of current microbiota-based approaches to enhance vaccine outcomes, and describe novel microbe-derived components that could lead to safer, more effective vaccines and vaccine adjuvants.",

author = "Anne Jordan and Carding, {Simon R.} and Hall, {Lindsay J.}",

note = "Funding Information: LJH is supported by Wellcome Trust Investigator Awards (100974/C/13/Z and 220876/Z/20/Z). LJH and SRC are also supported by Biotechnology and Biological Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1) and its constituent projects (BBS/E/F/000PR10353, BBS/E/F/000PR10355, and BBS/E/F/000PR10356), and a BBSRC Norwich Research Park Bioscience Doctoral Training grant (BB/M011216/1; supervisors LJH and SRC, student AJ). Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license",

year = "2022",

month = oct,

doi = "10.1016/S2666-5247(22)00185-9",

language = "English",

volume = "3",

pages = "e787--e794",

journal = "The Lancet Microbe",

issn = "2666-5247",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - The early-life gut microbiome and vaccine efficacy

AU - Jordan, Anne

AU - Carding, Simon R.

AU - Hall, Lindsay J.

N1 - Funding Information: LJH is supported by Wellcome Trust Investigator Awards (100974/C/13/Z and 220876/Z/20/Z). LJH and SRC are also supported by Biotechnology and Biological Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1) and its constituent projects (BBS/E/F/000PR10353, BBS/E/F/000PR10355, and BBS/E/F/000PR10356), and a BBSRC Norwich Research Park Bioscience Doctoral Training grant (BB/M011216/1; supervisors LJH and SRC, student AJ). Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

PY - 2022/10

Y1 - 2022/10

N2 - Vaccines are one of the greatest successes of public health, preventing millions of cases of disease and death in children each year. However, the efficacy of many vaccines can vary greatly between infants from geographically and socioeconomically distinct locations. Differences in the composition of the intestinal microbiome have emerged as one of the main factors that can account for variations in immunisation outcomes. In this Review, we assess the influence of the gut microbiota upon early life immunity, focusing on two important members of the microbiota with health-promoting and immunomodulatory properties: Bifidobacterium and Bacteroides. Additionally, we discuss their immune stimulatory microbial properties, interactions with the host, and their effect on vaccine responses and efficacy in infants. We also provide an overview of current microbiota-based approaches to enhance vaccine outcomes, and describe novel microbe-derived components that could lead to safer, more effective vaccines and vaccine adjuvants.

AB - Vaccines are one of the greatest successes of public health, preventing millions of cases of disease and death in children each year. However, the efficacy of many vaccines can vary greatly between infants from geographically and socioeconomically distinct locations. Differences in the composition of the intestinal microbiome have emerged as one of the main factors that can account for variations in immunisation outcomes. In this Review, we assess the influence of the gut microbiota upon early life immunity, focusing on two important members of the microbiota with health-promoting and immunomodulatory properties: Bifidobacterium and Bacteroides. Additionally, we discuss their immune stimulatory microbial properties, interactions with the host, and their effect on vaccine responses and efficacy in infants. We also provide an overview of current microbiota-based approaches to enhance vaccine outcomes, and describe novel microbe-derived components that could lead to safer, more effective vaccines and vaccine adjuvants.

UR - http://www.scopus.com/inward/record.url?scp=85138799668&partnerID=8YFLogxK

U2 - 10.1016/S2666-5247(22)00185-9

DO - 10.1016/S2666-5247(22)00185-9

M3 - Review article

AN - SCOPUS:85138799668

SN - 2666-5247

VL - 3

SP - e787-e794

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 10

ER -

The early-life gut microbiome and vaccine efficacy

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this